What matters most? Different stakeholder perspectives on estimands for an invented case study in COPD.

Autor: Keene ON; GlaxoSmithKline, Stockley Park, UK., Ruberg S; Analytix Thinking, LLC, Indianapolis, Indiana, USA., Schacht A; Lilly Deutschland, Bad Homburg, Germany., Akacha M; Novartis Pharma AG, Basel, Switzerland., Lawrance R; Adelphi Values, Bollington, UK., Berglind A; AstraZeneca, Gothenburg, Sweden., Wright D; AstraZeneca, Cambridge, UK.
Jazyk: angličtina
Zdroj: Pharmaceutical statistics [Pharm Stat] 2020 Jul; Vol. 19 (4), pp. 370-387. Date of Electronic Publication: 2020 Jan 09.
DOI: 10.1002/pst.1986
Abstrakt: In drug development, we ask ourselves which population, endpoint and treatment comparison should be investigated. In this context, we also debate what matters most to the different stakeholders that are involved in clinical drug development, for example, patients, physicians, regulators and payers. With the publication of draft ICH E9 addendum on estimands in 2017, we now have a common framework and language to discuss such questions in an informed and transparent way. This has led to the estimand discussion being a key element in study development, including design, analysis and interpretation of a treatment effect. At an invited session at the 2018 PSI annual conference, PSI hosted a role-play debate where the aim of the session was to mimic a regulatory and payer scientific advice discussion for a COPD drug. Including role-play views from an industry sponsor, a patient, a regulator and a payer. This paper presents the invented COPD case-study design and considerations relating to appropriate estimands are discussed by each of the stakeholders from their differing viewpoints with the additional inclusion of a technical (academic) perspective. The rationale for each perspective on approaches for handling intercurrent events is presented, with a key emphasis on the application of while-on-treatment and treatment policy estimands in this context. It is increasingly recognised that the treatment effect estimated by the treatment policy approach may not always be of primary clinical interest and may not appropriately communicate to patients the efficacy they can expect if they take the treatment as directed.
(© 2020 John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: